States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Investment to expand manufacturing and global medicine supply capacity
Marks first international filing for Evofem’s single-dose oral treatment
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Takeda will seek an external partner to leverage its cell therapy platform technologies
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
